Login to Your Account

Financings Roundup

Alnylam Bringing In $101M, Gearing Up For Second IND

By Karen Pihl-Carey

Thursday, December 14, 2006
On the heels of a stock surge that began when RNAi competitor Sirna Therapeutics Inc. received a hefty buyout offer from Merck & Co. Inc., Alnylam Pharmaceuticals Inc. is raising $101 million through the sale of common stock. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription